Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - An individual-level prescription database study

BMC Clinical Pharmacology

Volumn 7, Issue , 2007, Pages

  Hartz, Ingeborg ^a,b   Sakshaug, Solveig ^c   Furu, Kari ^c   Engeland, Anders ^c,d   Eggen, Anne Elise ^b   Njølstad, Inger ^b   Skurtveit, Svetlana ^b,c  

^a INLAND NORWAY UNIVERSITY OF APPLIED SCIENCES   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL TRIAL; DATA BASE; DRUG CHOICE; DRUG INFORMATION; DRUG USE; DRUG UTILIZATION; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; NORWAY; PRESCRIPTION; SEX DIFFERENCE; STATISTICAL ANALYSIS; ADULT; AGE; CLINICAL PRACTICE; DRUG ADMINISTRATION; FACTUAL DATABASE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; STATISTICS; TABLET;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NORWAY; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRAVASTATIN; PRESCRIPTIONS, DRUG; PYRROLES; SEX FACTORS; SIMVASTATIN; TABLETS;

EID: 39049166645     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-7-14     Document Type: Article

References (23)

1. Baigent C Keech A Kearney PM Blackwell L Buck G Pollicino C Kirby A Sourjina T Peto R Collins R Simes R Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 2005, 366:1267-1278. 10.1016/ S0140-6736(05)67394-1 16214597
2. Walley T Folino-Gallo P Stephens P Van Ganse E Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003 Br J Clin Pharmacol 2005, 60:543-551. 10.1111/ j.1365-2125.2005.02478.x 16236045
3. Drug sales statistics in Norway. Norwegian Institute of Public Health, Oslo Norway http://www.legemiddelforbruk.no/english
4. Hartz I Skurtveit S Furu K Njolstad I Eggen AE Why do sales of lipid-lowering drugs vary between counties in Norway? Evidence from the OPPHED Health Study 2000-2001 Scand J Prim Health Care 2006, 24:115-121. 10.1080/02813430500475365 16690561
5. The Norwegian Prescription Registry (NorPD) http://www.fhi.no/eway/ default.aspx?pid=238&trg=MainLeft_5853&MainArea_5811= 5853:0:15,3467:1:0:0:::0:0&MainLeft_5853=5825:56740::1:5857:2:::0:0
6. Furu K Strøm H Rønning M Skurtveit S Engeland A Tverdal A The Norwegian prescription database (NorPD) - a new register for pharmacoepidemiologic research covering a whole nation. 21st ICPE Nashville Pharmacoepidemiology and Drug Safety 2005, 14:S49.
7. Summary of product characteristics (SPC) of drugs licenced for use in Norway 2004 Norwegian: Felleskatalogen 2004
8. Kanstrup H Lassen JF Heickendorff L Lauritzen T Larsen ML Quality of lipid-lowering therapy in patients with ischaemic heart disease: a register-based study in 3477 patients J Intern Med 2004, 255(3):367-372. 10.1111/j.1365-2796.2003.01299.x 14871460
9. Norway Statistics. Population by sex and one-year age groups http://statbank.ssb.no//statistikkbanken/default_fr.asp?PLanguage=1
10. WHO collaborating centre for Drug Statistic and Methodology, ATC classification index with DDDs 2005, Oslo, Norway, 2004
11. Hartz I Eggen AE Grimsgaard S Skjold F Njølstad I Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study - the Tromsø Study 2001 Eur J Clin Pharmacol 2004, 60:643-649. 10.1007/s00228-004-0827-z 15455181
12. Tonstad S Rosvold EO Furu K Skurtveit S Undertretament and overtreatment with statins: the Oslo Health Study 2000-2001 J Intern Med 2004, 255:494-502. 10.1111/j.1365-2796.2004.01315.x 15049884
13. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002, 360:7-22. 10.1016/S0140-6736(02)09327-3 12114036
14. Riahi S Fonager K Toft E Hvilsted-Rasmussen L Bendsen J Paaske Johnsen S Sorensen HT Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark Br J Clin Pharmacol 2001, 52:307-311. 10.1046/ j.0306-5251.2001.01439.x 11560563
15. Mantel-Teeuwisse AK Klungel OH Verschuren WM Porsius AJ de Boer A Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol 2002, 53:379-385. 10.1046/j.1365-2125.2002.01562.x 11966669
16. Larsen J Andersen M Kragstrup J Gram LF Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population Eur J Clin Pharmacol 2001, 57:343-348. 10.1007/s002280100307 11549214
17. Kvan E Pettersen KI Landmark K Reikvam A Treatment with statins after acute myocardial infarction in patients >/= 80 years: underuse despite general acceptance of drug therapy for secondary prevention Pharmacoepidemiology and Drug Safety 2006, 15:261-267. 10.1002/pds.1172
18. Ose L Skjeldestad FE Bakken IJ Levorsen A Alemao EA Yin DD Borgstrom F Jonsson L Lipid management and cholesterol goal attainment in Norway American journal of cardiovascular drugs 2006, 6:121-128. 10.2165/ 00129784-200606020-00006 16555865
19. Larsen J Andersen M Kragstrup J Gram LF High persistence of statin use in a Danish population: compliance study 1993-1998 Br J Clin Pharmacol 2002, 53:375-378. 10.1046/j.1365-2125.2002.01563.x 11966668
20. Gislason GH Rasmussen JN Abildstrom SZ Gadsboll N Buch P Friberg J Rasmussen S Kober L Stender S Madsen M Torp-Pedersen C Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction Eur Heart J 2006, 27:1153-1158. 10.1093/eurheartj/ehi705 16399775
21. Shepherd J Blauw GJ Murphy MB Bollen EL Buckley BM Cobbe SM Ford I Gaw A Hyland M Jukema JW Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 2002, 360:1623-30. 10.1016/S0140-6736(02)11600-X 12457784
22. Treatment with lipid-lowering drugs in the prevention of cardiovascular disease [In Norwegian: Behandling med lipidsenkende legemidler for å forebygge hjerte-og karsykdom] Norwegian Medicines Agency, Oslo, Norway 2003
23. Rasmussen JN Gislason GH Abildstrom SZ Rasmussen S Gustafsson I Buch P Friberg J Kober L Torp-Pedersen C Madsen M Stender S Statin use after acute myocardial infarction: a nationwide study in Denmark Br J Clin Pharmacol 2005, 60:150-158. 10.1111/j.1365-2125.2005.02408.x 1604266